A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-BI and LDL receptors
Journal of Lipid Research
This study aimed to identify the mechanisms of the hypolipidemic action of the selective estrogen receptor modulator (SERM) acolbifene (ACOL). Four weeks of treatment with ACOL reduced fasting and postprandial plasma triglycerides (TGs), an effect associated with lower VLDL-TG secretion rate ( ؊ 25%), and decreased mRNA of microsomal triglyceride transfer protein (MTP; ؊ 29%). ACOL increased liver TG concentration ( ؉ 100%) and amplified the feeding-induced increase in the master lipogenicdoi:10.1194/jlr.m400448-jlr200 pmid:15741653 fatcat:h2vyyoi7xjggza6mgrmjuxpzxu